Highlights
- •Pharmacophore mapping of ROCK 2 inhibitors was carried outout.
- •Virtual screening and design of ROCK 2 inhibitorsinhibitors.
- •Molecular docking analysis resulted in benzthiazole analogsanalogs.
- •In silico ADMET study was carried out to design potential ROCK 2 inhibitors.
Graphical abstract
Graphical Abstract
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Multiple Sclerosis and Related DisordersAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction.Proc. Natl. Acad. Sci. USA. 2004; 101: 9121-9126https://doi.org/10.1073/pnas.0400520101
- Dose-dependent beneficial and detrimental effects of ROCK inhibitor Y27632 on axonal sprouting and functional recovery after rat spinal cord injury.Exp. Neurol. 2005; 196: 352-364https://doi.org/10.1016/j.expneurol.2005.08.011
- Fasudil regulates T cell responses through polarization of BV-2 cells in mice experimental autoimmune encephalomyelitis.Nat. Publ. Gr. 2014; 35: 1428-1438https://doi.org/10.1038/aps.2014.68
- Chroman-3-amides as potent Rho kinase inhibitors.Bioorg. Med. Chem. Lett. 2008; 18: 6406-6409https://doi.org/10.1016/j.bmcl.2008.10.080
- Discovery and optimization of indoles and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-I).Bioorg. Med. Chem. Lett. 2011; 21: 7107-7112https://doi.org/10.1016/j.bmcl.2011.09.083
- Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases.Drug Discov. Today. 2010; 15: 622-629https://doi.org/10.1016/j.drudis.2010.06.011
- Tetrahydroisoquinoline derivatives as highly selective and potent rho kinase inhibitors.J. Med. Chem. 2010; 53: 5727-5737https://doi.org/10.1021/jm100579r
- Pharmacophore modeling, virtual screening, and mo-lecular docking studies for discovery of novel Akt2 inhibitors.Int. J. Med. Sci. 2013; 10: 265-275https://doi.org/10.7150/ijms.5344
- Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.Bioorg. Med. Chem. Lett. 2007; 17: 2355-2360https://doi.org/10.1016/j.bmcl.2006.12.043
- Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors.J. Med. Chem. 2008; 51: 6642-6645https://doi.org/10.1021/jm800986w
- Principles of QSAR models validation: internal and external.QSAR Comb. Sci. 2007; 26: 694-701https://doi.org/10.1002/qsar.200610151
〈https://preadmet.bmdrc.kr/adme〉 (Accessed 19 April 2016).
〈http://www.organic-chemistry.org/prog/peo/〉 (Accessed 20 May 2016).
- Rho-kinase, a potential therapeutic target for the treatment of hypertension.Drug News Perspect. 2004; 17: 523-527https://doi.org/10.1358/dnp.2004.17.8.863696
- Investigation of structural requirements for inhibitory activity at the rat and housefly picrotoxinin binding sites in ionotropic GABA receptors using DISCOtech and CoMFA.Chemosphere. 2007; 69: 864-871https://doi.org/10.1016/j.chemosphere.2007.06.040
- Signaling to Rho GTPases.Exp. Cell Res. 1999; 253: 166-179https://doi.org/10.1006/excr.1999.4674
- Rho kinase (ROCK) inhibitors and their application to inflammatory disorders.Curr. Top. Med. Chem. 2009; 9: 704-723https://doi.org/10.2174/156802609789044452
- New Angle of View on the Role of Rho / Rho Kinase Pathway in Human Diseases.13. 2014: 378-395
- Wf-536 prevents tumor metastasis by inhibiting both tumor motility and angiogenic actions.Eur. J. Pharmacol. 2003; 459: 113-120https://doi.org/10.1016/S0014-2999(02)02869-8
- Effect of Wf-536, a novel ROCK inhibitor, against metastasis of B16 melanoma.Cancer Chemother. Pharmacol. 2003; 52: 319-324https://doi.org/10.1007/s00280-003-0641-9
- A comparison of the pharmacophore identification programs: catalyst, DISCO and GASP.J. Comput. Aided Mol. Des. 2002; 16: 653-681https://doi.org/10.1023/A:1021954728347
- Wide therapeutic time window for fasudil neuroprotection against ischemia-induced delayed neuronal death in gerbils.Brain Res. 2007; 1128: 175-180https://doi.org/10.1016/j.brainres.2006.10.027
- Design and synthesis of potent and selective azaindole-based Rho kinase (ROCK) inhibitors.ChemMedChem. 2008; 3: 1893-1904https://doi.org/10.1002/cmdc.200800211
- Design and synthesis of potent and selective azaindole-based Rho kinase (ROCK) inhibitors.ChemMedChem. 2008; 3: 1893-1904https://doi.org/10.1002/cmdc.200800211
- Benzimidazole- and benzoxazole-based inhibitors of Rho kinase.Bioorg. Med. Chem. Lett. 2008; 18: 6390-6393https://doi.org/10.1016/j.bmcl.2008.10.095
- Design and synthesis of Rho kinase inhibitors (I).Bioorg. Med. Chem. 2004; 12: 2115-2137https://doi.org/10.1016/j.bmc.2004.02.025
- Potential virtual lead identification in the discovery of renin inhibitors: application of ligand and structure-based pharmacophore modeling approaches.Eur. J. Med. Chem. 2011; 46: 2469-2476https://doi.org/10.1016/j.ejmech.2011.03.035
- Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension.Nature. 1997; 389: 990-994https://doi.org/10.1038/40187
〈www.nationalmssociety.org〉 (Accessed 22 May 2016).
- Reduction of intraocular pressure by topical administration of an inhibitor of the Rho-associated protein kinase.Curr. Eye Res. 2001; 22: 470-474https://doi.org/10.1076/ceyr.22.6.470.5489
- Benzothiazoles as Rho-associated kinase (ROCK-II) inhibitors.Bioorg. Med. Chem. Lett. 2009; 19: 6686-6690https://doi.org/10.1016/j.bmcl.2009.09.115
- Discovery of potent and selective urea-based ROCK inhibitors and their effects on intraocular pressure in rats.ACS Med. Chem. Lett. 2010; 1: 175-179https://doi.org/10.1021/ml1000382
Article info
Publication history
Published online: February 12, 2018
Accepted:
February 9,
2018
Received in revised form:
January 20,
2018
Received:
May 16,
2017
Identification
Copyright
© 2018 Elsevier B.V. All rights reserved.
